title: [The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
abstract: We present the results of a one-year follow-up study of 11 patients treated with gilenya. The results of cardiomonitoring (ECG and daily arterial pressure monitoring) during the treatment with the first dose of the drug are presented. No clinically significant disturbances of functions in patients without cardiovascular diseases were noted. In these cases, no progression of disease was identified. Relapses were not observed in 82% of patients.
authors.forename: S V
authors.initials: SV
authors.lastname: Kotov
authors.forename: S I
authors.initials: SI
authors.lastname: Fedorova
authors.forename: T I
authors.initials: TI
authors.lastname: Iakushina
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Lizhdvoĭ
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001794:Blood Pressure; D004562:Electrocardiography; D005260:Female; D000068876:Fingolimod Hydrochloride; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000503:physiopathology; D011409:Propylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D055502:Secondary Prevention; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine